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Abstract 
Loss of the E3 ubiquitin ligase Parkin causes early onset Parkinson disease, a 
neurodegenerative disorder of unknown etiology. Parkin has been linked to multiple 
cellular processes including protein degradation, mitochondrial homeostasis and 
autophagy, however, its precise role in pathogenesis is unclear. Recent evidence 
suggests Parkin is recruited to damaged mitochondria, possibly affecting 
mitochondrial fission and/or fusion, to mediate their autophagic turnover. The precise 
mechanism of recruitment and the ubiquitination target are unclear. Here we show in 
Drosophila cells that PINK1 is required to recruit Parkin to dysfunctional mitochondria 
and promote their degradation. Furthermore, PINK1 and Parkin mediate the 
ubiquitination of the pro-fusion factor Mfn on the outer surface of mitochondria. Loss 
of Drosophila PINK1 or parkin causes an increase in Mfn abundance in vivo and 
concomitant elongation of mitochondria. These findings provide a molecular 
mechanism by which the PINK1/Parkin pathway affects mitochondrial fission/fusion 
as suggested by previous genetic interaction studies. We hypothesize that Mfn 
ubiquitination may provide a mechanism by which terminally damaged mitochondria 
are labeled and sequestered for degradation by autophagy. 
 
\body 
Introduction 
Parkinson disease (PD) is a common, neurodegenerative disorder principally 
affecting the degeneration of nigral dopaminergic neurons. The pathogenic 
mechanisms are unknown but valuable insight has been gained from identifying gene 
mutations causative for familial forms of PD (1). Loss-of-function mutations in PINK1 
and parkin are the major cause of autosomal recessive, early onset PD. PINK1 
encodes a mitochondria targeted kinase (2) while parkin encodes an E3 ubiquitin 
 3 
ligase (3); a class of enzymes which conjugate ubiquitin to target substrates. This 
modification is usually considered in the context of substrate degradation by the 
proteasome, but ubiquitination also serves many other cellular functions. 
Consequently, much emphasis has been put on elucidating a link between Parkin 
dysfunction and protein aggregation. Despite the identification of numerous putative 
Parkin substrates, an unequivocal causative link between substrate aggregation and 
pathogenesis remains debatable.  
 There is strong evidence, however, that supports an important role for Parkin 
in regulating mitochondrial homeostasis (4). Studies have revealed a conserved 
function of Parkin acting downstream of PINK1 to protect mitochondrial integrity and 
prevent oxidative stress-induced apoptosis (5-8). Recently, we and others have 
reported that Drosophila parkin and PINK1 genetically interact with components of 
the mitochondrial fission and fusion machinery (9-12), suggesting that loss of 
PINK1/parkin function may lead to excess mitochondrial fusion. Consistent with this, 
mitochondrial elongation has been reported in cells derived from PD patients with 
parkin mutations (13). However, the effects of parkin or PINK1 deficiency in 
mammalian cells remain unresolved since additional reports describe inconsistent 
phenotypes in PINK1 and parkin deficient cells (6, 14-17). The reasons for this 
discrepancy are unclear but warrant further clarification. 
 Important insight into the mechanism by which Parkin regulates mitochondrial 
homeostasis has revealed that upon mitochondrial depolarization Parkin translocates 
from the cytoplasm to accumulate on a subset of mitochondria, and promotes their 
degradation by autophagy (18). It has also been proposed that regulated 
mitochondrial fission/fusion helps sort out damaged mitochondria for degradation 
(19-21). These findings raise the possibility that Parkin receives some signal 
identifying dysfunctional or damaged mitochondria, translocates and interacts with an 
unknown factor, to effect mitochondrial fission and/or fusion and promote mitophagy 
(22).  
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 Here we show that PINK1 is required for the recruitment of Parkin to 
damaged mitochondria and subsequent mitophagy, consistent with recent reports 
(23-25). Furthermore, we show that PINK1 and Parkin promote the ubiquitination of 
the pro-fusion factor Mfn. These findings suggest Mfn ubiquitination may provide a 
mechanism by which terminally damaged mitochondria are recognized for 
degradation by autophagy. 
 
Results 
PINK1 and Parkin knockdown causes mitochondrial elongation  
Our previous genetic interaction studies in vivo, using both loss- and gain-of-function 
assays, indicate that Drosophila PINK1 and Parkin act to promote fission and/or 
inhibit fusion of mitochondria. To extend this study we quantified mitochondrial 
morphology upon loss- or gain-of-function of parkin and PINK1, alongside key 
regulators of mitochondrial morphology, in Drosophila S2R+ cells.  
 RNA interference (RNAi) can be robustly achieved in Drosophila cells by 
incubation of long double stranded RNA molecules complementary to the target gene 
(26). We performed targeted RNAi against PINK1, parkin and the Drosophila 
homologs of Drp1, Fis1, Opa1, and Mfn1/2 (here called Mfn). RNAi of these targets 
typically caused ~90% knockdown of the endogenous message after 3 days (Fig. 
S1). We found that sample fixation grossly altered the mitochondrial morphology 
(Fig. S2A), so for this study cells were imaged live using the selective mitochondrial 
dye rhodamine 123 (Fig. 1A,C). As expected we found that knockdown of the pro-
fission genes Drp1 and Fis1 resulted in elongated mitochondria whereas knockdown 
of pro-fusion genes Opa1 and Mfn (also known as Marf) resulted in fragmented 
mitochondria. We found that knockdown of PINK1 or parkin caused a significant 
elongation of mitochondrial length. Elongated mitochondria were also seen when 
transfected mitoGFP was used to label mitochondria (Fig. S2B). Conversely, 
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overexpression of Opa1 and Mfn caused a hyper-fused network while 
overexpression of Drp1 and Fis1 caused fragmentation (Fig. 1B,D). Overexpression 
of parkin also caused fragmentation, however, the effect of PINK1 was not 
significant, suggesting PINK1 may not be limiting or may need to be activated itself to 
ectopically promote fragmentation.  
 The relative levels of key mitochondrial morphology factor transcripts were 
unchanged by parkin or PINK1 knockdown (Fig. S3A), indicating the morphology 
changes do not occur from a transcriptional response altering the abundance of 
fission of fusion genes. Also, in contrast to a previous report (8), we find Parkin 
protein levels are not changed in a PINK1 mutant (Fig. S3B). Together these 
observations are consistent with the PINK1/Parkin pathway modulating the action of 
mitochondrial fission/fusion proteins to alter morphology. 
 
PINK1 is required for Parkin translocation and Parkin-mediated mitophagy. 
The recent study by Narendra et al. revealed an important insight into the function of 
Parkin, reporting it translocates to dysfunctional mitochondria and promotes 
mitophagy (18). We sought to determine whether this was a conserved function. In 
wild type Drosophila cells Parkin-GFP typically showed a diffuse localization 
throughout the cytoplasm with occasional accumulations at mitochondria (Fig. 2A, 
and Fig. S4). Upon treatment with the mitochondrial uncoupling agent carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) or the oxidative stressor paraquat a large 
proportion of cells showed Parkin-GFP accumulated at or near mitochondria (Fig. 2A, 
and Fig. S5), while overall Parkin-GFP abundance remained constant (Fig. S3C). 
Prolonged exposure to CCCP also led to the autophagy dependent, but proteasome 
independent, loss of mitochondria (Fig. 2B, and Fig. S6). Consistent with previous 
reports Parkin was also required for CCCP-induced mitophagy in Drosophila cells 
(Fig. 2B). 
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 To extend this observation we addressed whether PINK1, which acts 
upstream of Parkin, may affect the recruitment of Parkin to mitochondria and their 
autophagic degradation. Following PINK1 RNAi knockdown, CCCP or paraquat 
induced Parkin-GFP recruitment to mitochondria was prevented (Fig. 2C,D). In 
addition, loss of PINK1 also abrogated mitophagy (Fig. 2B). These data are 
consistent with PINK1 acting upstream to promote Parkin recruitment to 
dysfunctional mitochondria which in turn promotes their degradation.  
 
Drosophila Mitofusin is ubiquitintated by PINK1/Parkin and accumulates in 
mutants 
From the previous observations, we hypothesized that Parkin translocates to 
damaged mitochondria to alter their fission/fusion ability and promote their 
degradation, presumably via its ubiquitin ligase activity. Thus, we sought to 
determine if any of the key mitochondrial morphology factors may be modified by 
ubiquitin, and whether such modifications are Parkin dependent.  
 Flag-tagged forms of Drp1, Opa1 and Mfn were co-expressed with 
hemagglutinin (HA)-tagged ubiquitin (HA-Ub) in Drosophila cells. Western blot 
analysis of these proteins revealed a single major band of the predicted size for Drp1 
(Fig. 3A, white arrow). Opa1 was present in a small amount of the full length form but 
predominantly in the processed form (Fig. 3A, white arrowhead), as previously 
reported (27). However, Mfn was detected as a number of high molecular weight 
isoforms (asterisks) in addition to the expected full length form (Fig. 3A, black 
arrowhead). The smallest Mfn isoform at ~91 kDa is consistent with the predicted 
size of the full length, unmodified form of Drosophila Mfn. 
 To assess whether these isoforms are ubiquitin modified, we performed co-
immunoprecipitation experiments against HA-Ub. Immunoprecipitates of Flag-tagged 
Drp1, Opa1 and Mfn were prepared and Western blots were probed with an antibody 
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against HA. HA-positive bands were detected in the Mfn (asterisks) and Opa1 (white 
diamonds) samples but not Drp1 (Fig. 3A). Comparison with Western blots probed 
against Flag showed bands of equivalent size for Mfn-Flag (Fig. 3A, asterisks), 
consistent with these isoforms being ubiquitinated. The smallest Mfn isoform was not 
HA-Ub–positive (Fig. 3A, black arrowhead) consistent with this isoform being 
unmodified.  Larger ubiquitinated isoforms of Opa1 are not detected by anti-Flag 
immunoblotting suggesting these are very low abundance.  
 We next tested whether this ubiquitination is Parkin dependent by performing 
the same analysis again following RNAi knockdown of parkin. We also addressed 
whether attenuating the pathway more generally may affect Mfn ubiquitination, so 
PINK1 RNAi knockdown was also performed. Western blots of whole cell lysates 
from parkin and PINK1 knockdown cells revealed a striking loss of the ubiquitinated 
forms of Mfn (Mfn-Ub) (Fig. 3B, asterisks; and Fig. S7A). Interestingly, this appeared 
to be accompanied by an accumulation of non-ubiquitinated Mfn. Following 
enrichment by immunoprecipitation low levels of Mfn-Ub were detected in parkin 
knockdown cells that were undetectable in whole cell lysates, likely reflecting 
incomplete RNAi knockdown. However, in PINK1 knockdown cells no ubiquitinated 
Mfn could be detected even upon immunoprecipitation (Fig. 3B). In contrast however, 
ubiquitinated forms of Opa1 were unchanged by the loss of parkin or PINK1 (Fig. 3B, 
white diamonds), suggesting this modification is not PINK1/Parkin dependent. Again 
no modification of Drp1 was observed or its abundance changed by parkin or PINK1 
RNAi. 
 To gain further evidence that Mfn ubiquitination may be mediated by Parkin 
we tested whether they may physically interact. Immunoprecipitation assays  
revealed that upon co-expression Parkin-GFP is detected in precipitates of Mfn-Flag 
(Fig. 3C). Together these data strongly support that Parkin mediates the 
ubiquitination of Mfn.  
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 We sought to extend this observation in vivo. Using antibodies against 
Drosophila Mfn we could detect full length Mfn and high molecular weight Mfn-Ub 
(Fig. 3D), consistent with that seen in vitro. These bands were absent upon Mfn 
RNAi knockdown in vivo (Fig. 3D) indicating the specificity of the antiserum. 
Consistent with our in vitro results, Mfn-Ub was greatly reduced in a parkin mutant 
background (Fig. 3D).  
 We have shown that PINK1 is required for Parkin recruitment to mitochondria, 
however, previous genetic experiments in vivo have shown that overexpression of 
parkin can compensate for loss of PINK1. Therefore, we addressed whether 
overexpressing parkin may restore Mfn ubiquitination in the absence of PINK1. In 
PINK1 RNAi knockdown cells only unmodified Mfn was seen (Fig. 4A), however, 
when Parkin was overexpressed in PINK1 RNAi cells, the Mfn-Ub isoforms were 
again detected (Fig. 4A). Conversely, if PINK1 was overexpressed in parkin RNAi 
cells Mfn-Ub isoforms were not restored (Fig. 4B), consistent with genetic 
experiments showing PINK1 overexpression cannot compensate for loss of parkin in 
vivo. 
 
 Ubiquitination is a common signal for the degradation of proteins and 
organelles. Since evidence indicates Parkin and PINK1 promote mitophagy, we next 
assessed whether Mfn abundance is altered by loss of parkin and PINK1. The steady 
state levels of endogenous Drosophila Mfn were determined in vitro and in vivo. 
Western blot of control treated cells and wild type flies showed a band of the 
predicted full length Mfn which was absent in Mfn RNAi knockdown cells or flies (Fig. 
5). parkin knockdown cells or park25 null mutant flies showed a significant increase in 
Mfn abundance (Fig. 5). Mfn was also significantly more abundant in PINK1 
knockdown or PINK1B9 null mutant flies (Fig. 5). Interestingly, the level of Complex 
Vα did not appreciably increase (Fig. S7B), however, this technique is not sensitive 
to small changes. These data indicate Mfn levels accumulate upon loss of 
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PINK1/parkin, consistent with their role in mitophagy, but likely reflects turnover of a 
small proportion of the entire mitochondrial content. 
 
 Since our evidence suggests that Parkin is recruited to mitochondria where it 
may ubiquitinate Mfn we addressed whether Mfn is required for Parkin translocation. 
Parkin-GFP localization upon CCCP and paraquat treatment was monitored as 
before, and compared with Mfn RNAi knockdown cells. Under control conditions we 
saw Parkin-GFP translocation comparable to previous results, however, in the 
absence of Mfn, Parkin-GFP translocation was not eliminated but the prevalence was 
markedly reduced (Fig. 6). As before, the overall abundance of Parkin-GFP was 
unaffected by treatments in Mfn RNAi cells (Fig. S3C). These results indicate Mfn is 
not an absolute requirement for Parkin translocation. 
 
Discussion 
Maintenance of mitochondrial homeostasis appears to be an important function of 
the PINK1/Parkin pathway in multiple model systems and is likely a key factor in 
mediating neurodegeneration. Recent studies have begun to shed light on the 
potential mechanism by which this pathway maintains a healthy mitochondrial 
population. Emerging evidence indicates that PINK1 is required to recruit Parkin to 
damaged or dysfunctional mitochondria, whereupon it promotes mitophagy (23-25). 
Regulated mitochondrial fission and fusion events are thought to contribute to a 
quality control mechanism to help 'sort out' terminally damaged mitochondria for 
degradation (19-21). Importantly, PINK1 and parkin have previously been shown to 
genetically interact with components of the mitochondrial fission/fusion machinery 
and affect mitochondrial morphology (9-12), however, the molecular mechanisms are 
not known. Here we provide further evidence that PINK1 is required for Parkin 
translocation to damaged mitochondria and that this pathway affects mitochondrial 
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morphology. We also provide evidence that the PINK1/Parkin pathway promotes the 
ubiquitination and regulates the levels of the pro-fusion protein Mfn, thus providing a 
potential molecular mechanism by which PINK1/Parkin may modulate mitochondrial 
dynamics.  
 Consistent with recent reports (23-25), we find that the translocation of Parkin 
to damaged mitochondria and their subsequent autophagy is dependent on PINK1. 
However, the molecular mechanisms that promote Parkin's recruitment to 
mitochondria are still unclear. PINK1's kinase activity, but not mitochondrial 
localisation, appears to be necessary for Parkin translocation (23-25). Since PINK1 
can be found extra-mitochondrially (27-30) and may directly phosphorylate Parkin 
(31, 32), this may be a mechanism to stimulate its translocation. Alternatively it may 
phosphorylate a Parkin substrate, e.g. Mfn, and thereby provide a recruitment signal. 
Interestingly, we find that loss of Mfn reduces but does not eliminate Parkin 
translocation. Recent evidence indicates Parkin also ubiqutinates VDAC on the outer 
mitochondrial surface (23), suggesting there may be multiple recruitment substrates. 
While further work will be required to elucidate these mechanisms, this provides a 
molecular basis for the genetic hierarchy in which PINK1 acts upstream of Parkin (5-
8). 
 In order to understand the role of Parkin translocation we took a candidate 
approach to identify putative substrates. Since the function of Parkin and PINK1, has 
been linked with mitochondrial dynamics we surveyed key components of the 
mitochondrial fission and fusion machinery for ubiquitin modification. We found that 
Mfn, which localizes to the outer surface of mitochondria, is ubiquitinated in a 
PINK1/Parkin dependent manner and accumulates upon loss of PINK1 or parkin. 
Interestingly, the ubiquitinated isoforms do not show a typical ubiquitination 'ladder' 
but instead appear to reflect a pattern of one and three or four ubiquitin adducts. 
While it remains to be shown that Parkin directly mediates this ubiquitination, there is 
evidence that Parkin can mediate mono-ubiquitination (33-37), K27 (23) and K63 
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linkages (38, 39). These modes of ubiquitination are not typically linked to 
proteasome degradation, and there is growing speculation that important pathogenic 
functions of Parkin may be proteasome-independent (reviewed in (40)). 
 Numerous elegant studies have demonstrated that the mitochondrial network 
is extremely dynamic and responds rapidly and reversibly to many physiological 
changes including potentially toxic challenges such as oxidative stress and calcium 
flux (reviewed in  (41, 42)). While mitochondrial remodeling can contribute to 
promoting cell death it can also act in a protective manner contributing to a quality 
control process that likely involves degradation by autophagy/lysosome. Recent work 
has reported observations that, following a fission event, regulated fusion of daughter 
mitochondria can determine whether they rejoin the network or are sequestered for 
degradation (19). Re-fusion appears to be dependent upon the recovery of 
mitochondrial membrane potential after division and likely represents a mechanism 
to 'sort out' terminally dysfunctional mitochondria (20). Since Mitofusins mediate the 
tethering and fusion of mitochondrial, via homo- and heterotypic interaction of their 
HR2 domains (43), we hypothesize that Parkin mediated Mfn ubiquitination may 
interfere with intermolecular interactions preventing fusion. Alternatively, Mfn 
ubiquitination may lead to a selective removal of Mfn from damaged mitochondria 
and thus reduce their re-fusion capacity of those mitochondria. Consistent with this, 
we find that loss of parkin or PINK1, and hence loss of ubiquitination, leads to 
increased Mfn levels and mitochondrial elongation, presumably due to excess fusion. 
Thus, Mfn ubiquitination may provide a signal that simultaneously prevents the re-
fusion of terminally damaged mitochondria and labels them for safe degradation by 
autophagy (22).  
 It is reasonable to suppose that under normal conditions the majority of 
mitochondria are relatively 'healthy' and thus mitochondrial turnover is an infrequent 
event. This is supported by the observation that Complex Vα levels are not 
significantly altered by decreased mitophagy. However, this rationale implies that Mfn 
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accumulates and is selectively ubiquitinated on mitochondria targeted for 
degradation but this remains to be shown. Interestingly, our findings provide a 
molecular mechanism that can explain the previously reported genetic interactions 
between PINK1 and parkin and the fission/fusion factors. In particular, that promoting 
mitochondrial fragmentation, by overexpression of Drp1 or reduction of Mfn and 
Opa1, is able to partially suppress the locomotor deficits, muscle degeneration and 
mitochondrial abnormalities (9-12). Together these findings suggest that aberrant 
accumulation of Mfn may mediate the loss of mitochondrial homeostasis caused by 
loss of PINK1 or parkin. While further work will be needed to determine whether this 
contributes to PD pathogenesis, our results support the emerging hypothesis that the 
PINK1/Parkin pathway acts to regulate the safe degradation of terminally damaged 
mitochondria as a quality control mechanism (22, 44). 
 
Materials and Methods 
Cell culture and transfection   
S2R+ cells were cultured in Schneider’s medium (Invitrogen) supplemented with 5% 
fetal calf serum (Sigma) and 1% penicillin-streptomycin (Invitrogen-Gibco). Cells 
were transfected using Effectene reagent (Qiagen) following manufacturer's 
instructions and collected after 24-48hrs. 500µM copper sulfate solution was added 
to the cells to induce plasmid expression when required. Where indicated cells were 
treated with 10µM CCCP for 2 hrs or 10mM paraquat for 6 hrs. 
 
RNAi treatment and quantification 
Double stranded RNAs were prepared using MEGA script kit (Ambion). Primers used 
to generate dsRNAs are described in Supplementary material. 1.2 million cells were 
plated on 6 well plate and treated with 15µg dsRNA probe in serum free medium. 
 13 
Two hours after probe treatment, complete medium was added to the wells and cells 
were cultured for 2 days before being transfected. 
 For mRNA quantification total RNA was extracted using TRI Reagent (Sigma) 
or RNeasy Mini Kit (Qiagen) following manufacturer’s instruction. 1.5µg total RNA 
was reverse-transcribed by using a random decamer primer (RETROscript kit, 
Ambion). Quantitative real-time PCR was performed using the SYBR Green Master 
Mix method (Sigma) with a Bio-Rad MyiQ system. Full details are in Supplementary 
Information. 
 
Immunoblotting and immunoprecipitation 
Standard protocols were used for Western blotting. The following commercial 
antibodies were used: anti-Complex Vα (1:5000, MitoSciences), anti-Flag (1:1000, 
Cell Signaling), anti-HA (1:1000, Cell Signaling), anti-Actin(1:10000, Chemicon), anti-
α-Tubulin (1:10000, Sigma), and anti-GFP (1:2000, Abcam), and anti-Myc (1:1000, 
Cell Signaling). Anti-Parkin (1:3000) has been described before. Anti-Mfn (1:2000) 
was raised in rabbit against an N-terminal peptide, DTVDKSGPGSPLSRF. Detection 
was done using HRP-conjugated secondary antibodies and ECL 
chemiluminescence. For immunoprecipitation cells were lysed in standard lysis buffer 
(see SI for details). Anti-Flag (1:50) or anti-GFP (1:200) antibodies were conjugated 
to Protein A agarose beads and incubated with 1mg of whole-cell extract overnight 
and extracted with 4X Laemmli buffer. 
 
Cell imaging 
Cells were plated on imaging dishes and treated as indicated. For mitochondrial 
morphology analysis; live cells were incubated with 200µM rhodamine 123 and 
imaged live in growing medium. Quantification of mitochondria length was performed 
by using ImageJ software as previously described (45). For transfected cells; 
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following treatment, cells were fixed with paraformaldehyde and prepared by 
standard protocols for immunocytochemistry: Hoechst (2µg/ml), phalloidin Alexa-
Fluor488 (2units), anti-Complex Vα (1:1000). All images were acquired on a 
DeltaVision DV microscope using standard epifluorescence. Unless stated images 
were deconvolved after acquisition to improve image clarity and sharpness. 
 
Drosophila stocks and procedures 
Drosophila were raised under standard conditions at 25oC. park25 and PINK1B9 
mutants and UAS-parkin have been described before (46), (7). w1118 and da-GAL4 
strains were obtained from the Bloomington Drosophila Stock Center, and UAS-Mfn-
RNAi from the Vienna Drosophila Research Centre. UAS-Mfn3 was constructed by 
cloning the entire Drosophila Mfn open reading frame from cDNA (RE04414) into 
pUAST vector, which was injected into w1118 embryos for germline transformation 
(BestGene Inc.). Multiple independent lines were isolated and assessed.  
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Figure Legends 
Figure 1. Drosophila PINK1 and parkin activity promotes mitochondrial fission 
and/or inhibits fusion. (A) S2R+ cells were treated with the indicated RNAi probe 
for 3 days. Rhodamine 123 was used to visualize mitochondrial morphology in live 
cells. (B) S2R+ cells were transfected with plasmids to express indicated genes and 
co-transfected with mitoGFP in order to visualize mitochondria. (C,D) Quantification 
of mitochondrial length as imaged in (A) and (B) respectively. Two control (ctrl) RNAi 
and vector only treatments are shown to demonstrate phenotype variability. Scale 
bar is 5 µm. The bar graphs represent the mean and s.e.m. for at least three 
independent experiments. Significance was determined by one-way ANOVA with 
Bonferroni correction (** P<0.01, *** P<0.001). 
 
Figure 2. PINK1 is required for Parkin translocation and mitophagy. (A) S2R+ 
cells co-transfected with parkin-GFP and mitoDsRed, treated with control dsRNA 
then treated with CCCP or paraquat, and fixed for imaging. Most Parkin-GFP puncta 
co-localize with (arrow) or abut (arrowhead) mitochondria. (B) Cells were treated with 
indicated dsRNAs and exposed to CCCP for 24 hours. Samples were fixed and 
stained to label mitochondria (anti-Complex Vα, red), actin (phalloidin-488, green) or 
nuclei (Hoechst, blue). (C) S2R+ cells transfected as in (A) and treated with PINK1 
dsRNA before exposure to CCCP or paraquat. Comparison of Parkin-GFP 
distribution under different image analysis methods is shown in Fig. S5. (D) 
Percentage of cells with Parkin-GFP puncta. Scale bar is 5 µm. The bar graphs 
represent the mean and s.e.m. of at least four independent tests. Significance was 
determined by one-way ANOVA with Bonferroni correction (*** P<0.001). 
 
Figure 3. Mfn is ubiquitinated in a PINK1/Parkin dependent manner in vitro and 
in vivo. (A) S2R+ cells co-transfected with HA-Ub plus empty vector or Flag-tagged 
Mfn, Drp1 or Opa1 plasmids as indicated, were immunoprecipitated and subjected to 
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Western blot analysis. (B) S2R+ cells were treated with control, parkin and PINK1 
RNAi before being transfected as indicated. Cells were harvested and subjected to 
Western blot analysis as shown. Samples were also subjected to 
immunoprecipitation and Western bots probed with antibodies against Flag and HA. 
(C) Immunoprecipitates of S2R+ cells expressing combinations of empty vector, 
parkin-GFP and Mfn-Flag as shown. (D) Western blot analysis of Drosophila Mfn 
levels in vivo. A non-specific band seen in all samples is denoted 'ns'. Complex Vα 
and Actin are used as loading controls. Genotypes: w1118, wild type; Mfn RNAi, da-
GAL4,UAS-Mfn-RNAi; Mfn overexpression, da-GAL4,UAS-Mfn; Mfn overexpression 
park25, da-GAL4,UAS-Mfn,park25/park25; park25, park25/park25. In all panels, black 
arrowheads indicate full length Mfn, asterisks are ubiquitinated Mfn, white 
arrowheads denote full length Opa1, white diamonds are ubiquitinated Opa1, and 
white arrows show full length Drp1. 
 
Figure 4. Parkin overexpression can cause Mfn ubiquitination in the absence of 
PINK1. (A) S2R+ cells were treated with control or PINK1 RNAi probe and 
transfected with combinations of empty vector, parkin-GFP and Mfn-Flag, as shown. 
(B) S2R+ cells were treated with control or parkin RNAi probe and transfected with 
combinations of empty vector, PINK1-myc and Mfn-Flag, as shown. Cells were 
harvested and subjected to Western blot analysis using specific antibodies indicated.  
 
Figure 5. Mfn accumulates in the absence of PINK1/Parkin. (A) S2R+ cells were 
treated with RNAi probe as indicated, harvested and subjected to Western blot 
analysis by using antibodies against Drosophila Mfn. Antibodies against Complex Vα 
and Actin are used as loading controls. (B) Wild type and mutant animals were 
collected and subjected to Western blot analysis. Genotypes: w1118, wild type; Mfn 
RNAi, da-GAL4,UAS-Mfn-RNAi; park25, park25/park25; PINK1B9, PINK1B9/Y. 
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Quantification of Mfn levels relative to Complex Vα loading control in S2R+ cells (C) 
and wild type and mutant animals (D). Charts represent mean and s.e.m. for three 
independent experiments. Significance was determined by one-way ANOVA with 
Bonferroni correction (** P<0.01, *** P<0.001).  
 
Figure 6. Loss of Mfn partially impairs Parkin translocation to mitochondria. 
S2R+ cells were co-transfected with plasmids expressing parkin-GFP and 
mitoDsRed and treated with control RNAi probe or Mfn RNAi probe before being 
treated with CCCP or Paraquat and analysed for Parkin-GFP accumulation. Control 
RNAi treated cells are represented in Fig. 2. (A) Mfn RNAi treated cells exposed to 
CCCP, Paraquat or no stress. Two representative images are shown for each 
treatment to show variability. Scale bar is 5 µm. (B) Percentage of cells with green 
puncta. The chart shows the mean and s.e.m. for counting of at least four 
independent well fields containing 70-90 cells/field. Significance was determined by 
one-way ANOVA with Bonferroni correction (* P<0.05, *** P<0.001). 
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